Loading
Pacira BioSciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Brege Laura, was filed 19 Aug 2024.
Insider Decl.
711
Thresholds
n/a
Buy Volume
€990,313
18 ops. · all time
Sell Volume
€113M
325 ops. · all time
Who traded when
BuySaleShawn Cross7 sales
Lauren Riker3 sales
Slonin Jonathan3 sales
Williams Kristen2 sales
Ceesay Abraham1 sale
Gaugler Daryl1 sale
+2 other insiders
Since the insiders bought
- +79.9%Entry US$13.89 · Close at T+365 US$24.99
- +79.9%Entry US$13.89 · Close at T+365 US$24.99
- +85.6%Entry US$13.35 · Close at T+365 US$24.78
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Pacira BioSciences, Inc. Hold (neutral), based on 7 analysts. Average price target: US$33.57.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 14,785 of 26,284 companies
47.8
score / 100
Value49
Quality47
FCF yld9.4%
Earn yld0.5%
EV/EBITDA15.3x
ROE2.0%
Gross mgn79%
Net mgn1.0%
Debt/EBITDA3.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$36.38
Analyst consensus
7 analystsHold
US$25.00Target US$33.57(-8%)US$36.50
Income statement
RevenueUS$726.4M
Gross profitUS$576.7M79% margin
EBITDAUS$122.5M17% margin
Net incomeUS$7M2.0% margin
Valuation
PER (trailing)103.9x
PER (forward)10.5x
P/Book2.2x
Beta0.25
Balance sheet & cash
Market capUS$1.5B
Total debtUS$418.2M
Free Cash FlowUS$136.7M
Debt / Equity61%
Profitability & ownership
ROE2.0%
ROA1.5%
% insiders1.3%
% institutions105.9%
Last declaration on 9 October 2026
Declarations711 total
6,000 shares@ US$32.350.014% mcap19.8% of flowCommon StockSEC:0001628280-26-065566:0
6,000 shares@ US$36.320.015% mcap38.4% of flowCommonSEC144:0001959173-26-007312
3,040 shares@ US$23.230.0042% mcap7.2% of flowCommonSEC144:0001959173-26-006073
9,039 shares@ US$23.2740.021% mcap76.8% of flowCommonSEC144:0001959173-26-004600
6,405 sharesCommon StockSEC:0001628280-26-043004:0
6,405 sharesCommon StockSEC:0001628280-26-043002:0
6,405 sharesCommon StockSEC:0001628280-26-043008:0
6,115 shares@ US$23.500.014% mcap39.7% of flowCommonSEC144:0001959173-26-004550
10,259 shares@ US$22.270.022% mcap27.4% of flowCommonSEC144:0001959173-26-004324
12,941 shares@ US$16.450.021% mcap12.4% of flowCommon StockSEC:0001628280-26-027287:0
12,941 shares@ US$25.160.032% mcap19.0% of flowCommon StockSEC:0001628280-26-027287:1
7,714 shares@ US$16.450.012% mcap7.3% of flowCommon StockSEC:0001628280-26-026669:0
7,714 shares@ US$25.140.019% mcap11.2% of flowCommon StockSEC:0001628280-26-026669:1
2,845 shares@ US$16.450.0045% mcap2.7% of flowCommon StockSEC:0001628280-26-026669:2
2,845 shares@ US$25.010.0069% mcap4.1% of flowCommon StockSEC:0001628280-26-026669:3
1,500 shares@ US$16.450.0024% mcap1.4% of flowCommon StockSEC:0001628280-26-026669:4
1,500 shares@ US$25.010.0037% mcap2.2% of flowCommon StockSEC:0001628280-26-026669:5
3,261 shares@ US$22.827.6% of flowCommon StockSEC:0001628280-26-019891:0
500 shares@ US$21.8111.8% of flowCommon StockSEC:0001628280-26-019890:0
6,163 shares0Common StockSEC:0001628280-26-019892:0
49,091 shares0Common StockSEC:0001628280-26-008080:0
54,546 shares0Common StockSEC:0001628280-26-008078:0
19,273 shares0Common StockSEC:0001628280-26-008076:0
261,818 shares0Common StockSEC:0001628280-26-008074:0
51,714 shares0Common StockSEC:0001628280-26-008077:0
25 of 711 declarations
About Pacira BioSciences, Inc.
From August 12 to August 16, 2024, 5 filers at Pacira BioSciences, Inc. bought shares for EUR 196,955 in total, the one notable purchase window at this US healthcare and pharma company, valued at USD 1.5 billion. Across the record, 18 purchases come to EUR 990,313 (median EUR 35,167), 10 of them filings flagged as clustered, against 325 sales worth EUR 113.2 million (median EUR 113,122).
Gary W. Pace, Director, bought EUR 182,066 on November 19, 2018 and EUR 179,359 on November 7, 2018. Andreas Wicki, Director, holds the three largest sales: EUR 5,853,134 on August 12, 2020, EUR 4,614,034 on March 10, 2021 and EUR 3,692,527 on March 11, 2021.
Read moreShow less
David M. Stack, CEO and Chairman, signs 116 of the 711 filings, 62 of them sales; Kristen Marie Williams signs 83. Annual volume peaks at 118 in 2022 and 115 in 2020, against 33 in 2025. Over the last twelve months: 45 filings, 13 sales, no purchase. For the 18 purchases with a result, the 90-day median is 12.3%, with 61% of results positive (recorded past results, not a forecast).
